iifl-logo-icon 1

Lyka Labs Ltd Share Price

116.39
(-1.34%)
Jul 19, 2024|09:44:59 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open117.97
  • Day's High118.52
  • 52 Wk High144.3
  • Prev. Close117.97
  • Day's Low116.02
  • 52 Wk Low97.9
  • Turnover (lac)22.24
  • P/E0
  • Face Value10
  • Book Value26
  • EPS0
  • Mkt. Cap (Cr.)415.4
  • Div. Yield0
No Records Found

Lyka Labs Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

117.97

Prev. Close

117.97

Turnover(Lac.)

22.24

Day's High

118.52

Day's Low

116.02

52 Week's High

144.3

52 Week's Low

97.9

Book Value

26

Face Value

10

Mkt Cap (₹ Cr.)

415.4

P/E

0

EPS

0

Divi. Yield

0

Lyka Labs Ltd Corporate Action

18 Jan 2024

12:00 AM

EGM

arrow

10 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

10 Jul 2023

12:00 AM

BookCloser

arrow

10 Jul 2023

12:00 AM

AGM

Announcement Date: 10 Jul, 2023

arrow

Lyka Labs Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Lyka Labs Ltd SHAREHOLDING SNAPSHOT

20 Jul, 2024|10:40 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 58.10%

Foreign: 0.00%

Indian: 58.10%

Non-Promoter- 0.90%

Institutions: 0.90%

Non-Institutions: 40.99%

Custodian: 0.00%

Share Price

Lyka Labs Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

48.13

28.69

28.69

28.69

Preference Capital

1.08

0.78

0.71

0.64

Reserves

28.3

15.75

-24.28

-9.91

Net Worth

77.51

45.22

5.12

19.42

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

164.34

62.26

33.67

41.68

yoy growth (%)

163.95

84.92

-19.21

-46.56

Raw materials

-30.86

-23.52

-15.48

-21.53

As % of sales

18.77

37.77

45.99

51.66

Employee costs

-16.21

-13.02

-10.57

-10.89

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

64.9

-16.96

-24.24

-12.69

Depreciation

-15.38

-8.04

-5.64

-6.3

Tax paid

-20.33

3.93

-1.19

0.38

Working capital

29.28

5.11

-23.18

16.67

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

163.95

84.92

-19.21

-46.56

Op profit growth

575.87

-742.93

333.98

-102.37

EBIT growth

887.98

-262.21

7.28

-127.49

Net profit growth

-375.97

-72.81

390.71

5,718.25

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

111.19

93.07

194.08

86.25

61.49

Excise Duty

0

0

0

0

0

Net Sales

111.19

93.07

194.08

86.25

61.49

Other Operating Income

0

0

0

0

0

Other Income

1.45

3.4

2.09

1.56

3.09

Lyka Labs Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,594.25

125.293,82,370.02867.60.855,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,584.8

77.221,21,645.675310.652,259507.93

Cipla Ltd

CIPLA

1,506.65

32.741,21,616.251,038.40.563,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,185.65

34.71,19,268.911,405.20.253,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,667.5

25.951,11,193.661,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Lyka Labs Ltd

Management

Register Office

Registrar Office

Chairman & MD & CEO

KUNAL NARENDRA GANDHI

Non-Exec. & Independent Dir.

Sandeep P Parikh

Executive Director & CFO

Yogesh B Shah

Non-Exec. & Independent Dir.

Dhara P. Shah

Company Sec. & Compli. Officer

Kishore P Shah

Independent Director

Babulal Jain

Director

Prashant Godha

Director

Shashil Mendonsa

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Initially manufacturing formulations, Lyka Labs brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. 83. It also added a range of ayurvedic and animal health care products over the years. In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan. Lyka Exports is the subsidiary of the company. The company offers a broad range of antibiotics used as life-savers and to treat minor infections. It has a fairly widespread product base with tropical steroids for skin disorders, anti-cancer products, cardio-vascular drugs and anti-inflammatory products. Lyka introduced, in India, cough lozenges containing dextromethorphan hydrobromide (DMR), favoured internationally as an effective and safe cough suppressant. Lyka has two formulations division and a bulk drugs division. It also set up additional manufacturing facilities for ointments. As part of its diversification, it has invested in Relic Finance, a company carrying on the business of finance and merchant banking.A GOI-recognised Export House, it received the Certificate of Merit for its excellent export performance in 1993-94. In the same year, it received an award from CHEMEXCIL for its outstanding performance.During 1997-98, the companys administrative office & plant at tarapur has been awarded ISO 9002 certification for its quality management system
Read More

Company FAQs

What is the Lyka Labs Ltd share price today?

Down Arrow

The Lyka Labs Ltd shares price on N/A is Rs.₹115.4 today.

What is the Market Cap of Lyka Labs Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lyka Labs Ltd is ₹411.86 Cr. as of 19 Jul ‘24

What is the PE and PB ratio of Lyka Labs Ltd?

Down Arrow

The PE and PB ratios of Lyka Labs Ltd is 0 and 4.14 as of 19 Jul ‘24

What is the 52 Week High and Low of Lyka Labs Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Lyka Labs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Lyka Labs Ltd is ₹99.95 and ₹143.5 as of 19 Jul ‘24

What is the CAGR of Lyka Labs Ltd?

Down Arrow

Lyka Labs Ltd's CAGR for 5 Years at 42.01%, 3 Years at 25.05%, 1 Year at 5.97%, 6 Month at -1.75%, 3 Month at -8.63% and 1 Month at 8.75%.

What is the shareholding pattern of Lyka Labs Ltd?

Down Arrow

The shareholding pattern of Lyka Labs Ltd is as follows:
Promoters - 58.10 %
Institutions - 0.90 %
Public - 40.99 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.